Drug Profile
LA 230
Latest Information Update: 29 Jul 2022
Price :
$50
*
At a glance
- Originator Lacer
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 27 Jul 2022 Lacer has been acquired by Italfarmaco
- 01 Nov 2000 Discontinued - Preclinical for Hyperlipidaemia in Spain (unspecified route)
- 01 Nov 2000 Discontinued - Preclinical for Hypertension in Spain (unspecified route)